Antimicrobial Resistance

Antimicrobial Resistance (AMR) is the phenomenon where microorganisms like bacteria and viruses evolve to resist drugs that were previously effective for treating infections. It is a major global public health threat. In enterprise risk management, AMR is classified as a biohazard and a business continuity risk. Organizations in life sciences must adhere to standards like **ISO 15189:2022** (Medical laboratories — Requirements for quality and competence) to establish and validate reliable AMR detection workflows, such as genomics-based surveillance. This standard ensures the accuracy and traceability of test results, which is critical for AMR monitoring and control.

Enterprises can manage AMR risks by implementing a genomic surveillance workflow. Key steps include: 1. **Standardized Testing**: Implement Whole-Genome Sequencing (WGS) and use an ISO-certified bioinformatics platform (like abritAMR) to detect AMR genes. This ensures process validation and accuracy, achieving metrics like 99.9% accuracy as cited in the reference article. 2. **Data Analysis & Risk Assessment**: Utilize the platform to classify AMR determinants and generate structured reports. This data allows for predicting phenotypic resistance with high accuracy (e.g., 98.9%) and assessing risk levels. 3. **Response & Reporting**: Based on the assessment, update clinical guidelines, implement infection control measures, and report to public health authorities. This demonstrates compliance with Good Clinical Practice (GCP) and reduces regulatory risks.

Taiwan enterprises face three main challenges in implementing AMR genomic surveillance: 1. **High Technical Barrier**: WGS and bioinformatics require significant investment in equipment and expertise. Solution: Adopt certified, automated platforms to standardize analysis and partner with external consultants for initial setup and training. 2. **Lack of Data Standardization**: Data formats vary across institutions, hindering large-scale analysis. Solution: Implement international data standards like those from WHO GLASS or **ISO/TS 20428:2017** to ensure interoperability. 3. **Difficulty in Proving ROI**: The long-term benefits are hard to quantify against the high initial cost. Solution: Establish key performance indicators (KPIs), such as reduction in infection rates of specific resistant strains, to demonstrate tangible returns on investment.

Winners Consulting specializes in antimicrobial resistance (AMR) management for Taiwan enterprises. We deliver compliant, ISO 15189-aligned genomic surveillance and data management systems within 90 days, enhancing your risk management capabilities. Free consultation: https://winners.com.tw/contact